PACB Stock Overview
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pacific Biosciences of California, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.36 |
| 52 Week High | US$14.55 |
| 52 Week Low | US$1.25 |
| Beta | 1.83 |
| 1 Month Change | -62.33% |
| 3 Month Change | -80.85% |
| 1 Year Change | -86.36% |
| 3 Year Change | -95.96% |
| 5 Year Change | -81.60% |
| Change since IPO | -91.73% |
Recent News & Updates
Recent updates
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16
Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?
Jul 31Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Jul 06Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Mar 29Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?
Feb 26Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook
Aug 08Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio
Jul 27Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?
Jul 11Pacific Biosciences Hit By Sentiment, But The Future Of Long-Read Sequencing Is Strong
Apr 05Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?
Feb 24Shareholder Returns
| PACB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -2.9% | 4.1% | 1.2% |
| 1Y | -86.4% | 4.7% | 24.9% |
Return vs Industry: PACB underperformed the US Life Sciences industry which returned 4.7% over the past year.
Return vs Market: PACB underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| PACB volatility | |
|---|---|
| PACB Average Weekly Movement | 17.9% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PACB's share price has been volatile over the past 3 months.
Volatility Over Time: PACB's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 796 | Christian O. Henry | www.pacb.com |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
Pacific Biosciences of California, Inc. Fundamentals Summary
| PACB fundamental statistics | |
|---|---|
| Market cap | US$400.25m |
| Earnings (TTM) | -US$306.73m |
| Revenue (TTM) | US$200.52m |
1.8x
P/S Ratio-1.2x
P/E RatioIs PACB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PACB income statement (TTM) | |
|---|---|
| Revenue | US$200.52m |
| Cost of Revenue | US$142.32m |
| Gross Profit | US$58.20m |
| Other Expenses | US$364.93m |
| Earnings | -US$306.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 29.02% |
| Net Profit Margin | -152.97% |
| Debt/Equity Ratio | 127.3% |
How did PACB perform over the long term?
See historical performance and comparison